Ci gaba a Maganin Farko ga Manya B-ALL: Cikakken Bayani daga The Lancet Hematology
A cikin wani sharhi mai cike da tarihi da aka buga a cikin Nazarin Haihuwar Lancet, kwararru sun yi cikakken bayani game da ci gaban da aka samu kwanan nan a fannin maganin cutar sankarar jini ta manya B-cell Acute Lymphoblastic Leukemia (B-ALL), inda suka jaddada muhimmancin dabarun magani na musamman da kuma haɗa sabbin hanyoyin rigakafi. A cikin shekaru goma da suka gabata, maganin cutar sankarar jini ta manya B-ALL da aka gano ta samu ci gaba mai yawa saboda fahimtar ilimin halittar cutar, ci gaban hanyoyin auna ƙarancin sauran cututtuka (MRD), da kuma haɗa magungunan da aka yi wa wahayi zuwa ga yara (PIR) don samun sakamako mafi kyau.
Binciken ya nuna cewa yayin da manya marasa lafiya na B-ALL ke ci gaba da fuskantar ƙalubale tare da gazawar magani da kuma yawan mace-mace idan aka kwatanta da yara, wasu muhimman dabaru suna inganta hasashen cutar. Ga ƙananan marasa lafiya, amfani da magungunan da aka yi wahayi zuwa ga yara ya tabbatar da inganci fiye da magungunan gargajiya na manya, tare da tsawon rai na dogon lokaci har zuwa 78%. Duk da cewa fa'idar waɗannan magungunan yana raguwa da shekaru, hanyar har yanzu tana ba da ci gaba mai mahimmanci, musamman idan aka haɗa ta da magungunan zamani kamar tyrosine kinase inhibitors (TKI) don Philadelphia chromosome-positive (Ph+) B-ALL.
Bugu da ƙari, haɗa magungunan rigakafi kamar anti-CD20 monoclonal antibodies (misali, Belantamab Mafodotin da Inotuzumab Ozogamicin) cikin ka'idojin magani na farko ya nuna alƙawarin rage guba da ke da alaƙa da chemotherapy da haɓaka ƙimar amsawa. Nazarin ya nuna cewa waɗannan magunguna, idan aka yi amfani da su tare da chemotherapy na gargajiya, suna ƙara yawan gafara sosai, musamman a cikin nau'ikan kwayoyin halitta masu haɗari na B-ALL.
Ga tsofaffi marasa lafiya (fiye da shekaru 60), wani sabon zamani na magani ya fito tare da amfani da ƙananan ƙwayoyin cuta tare da maganin rigakafi. Waɗannan hanyoyin suna da nufin rage nauyin chemotherapy, suna ba da zaɓi mafi aminci kuma mafi jurewa ga wannan rukunin masu rauni. Nazarin asibiti yana ci gaba da bincika haɗin kai mafi kyau na waɗannan hanyoyin, gami da amfani da magungunan ƙwayoyin CAR-T da magunguna da aka yi niyya, don ƙara inganta sakamako.
Binciken ya kammala da cewa yayin da aka samu ci gaba mai yawa wajen inganta jiyya ta farko ga manya B-ALL, ci gaba da bincike da gwaje-gwaje na asibiti suna da mahimmanci don magance gibin magani, musamman ga marasa lafiya masu haɗari da tsofaffi. Tsarin magani na musamman bisa ga bayanan kwayoyin halitta da kwayoyin halitta, da kuma ci gaba da haɓaka magungunan rigakafi, suna ba da bege ga mafi kyawun sakamako a nan gaba.
Wannan cikakken bincike na maganin B-ALL yana nuna muhimmin lokaci a ci gaba da yaƙi da wannan ƙalubalen ciwon daji na jini, wanda ke kawo sabon bege ga marasa lafiya a duk duniya.